These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6162721)

  • 1. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.
    Collen D; Verstraete M
    Thromb Res; 1979; 14(4-5):631-9. PubMed ID: 90396
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
    Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
    J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
    Takada A; Takada Y; Uemura K; Nakajima S; Ryu H; Ninchoji T
    Thromb Res; 1979; 15(5-6):889-94. PubMed ID: 115108
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage.
    Hayashi S; Yamada K
    Thromb Res; 1979; 16(3-4):393-400. PubMed ID: 92817
    [No Abstract]   [Full Text] [Related]  

  • 6. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Do thrombolytic agents prevent postphlebitis thromboembolism?].
    Trübestein G
    Haemostasis; 1986; 16 Suppl 4():40-53. PubMed ID: 3490419
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antithrombin III, alpha 2-macroglobulin, alpha 1-antitrypsin and plasminogen in childhood diabetes].
    Kotschy M; Wasikowa R; Iwanicka Z; Ciosek W
    Pol Tyg Lek; 1984 Apr; 39(18):611-3. PubMed ID: 6085653
    [No Abstract]   [Full Text] [Related]  

  • 9. [A study of antithrombin systems during heparin therapy].
    Boneu B; Immaculato F; Sie P; Caranobe C; Chamontin B; Guittard J
    Nouv Presse Med; 1982 Oct; 11(41):3043-6. PubMed ID: 6183640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of dextran sulfate in urokinase therapy and evaluation of the effects by estimation of plasmin inhibitor, fibrinogenolytic degradation products, and fibrinolytic degradation products.
    Hasegawa H; Nagata H; Yamauchi M; Murakoshi T; Oguma Y; Takei H; Seya T; Murao M
    Jpn Heart J; 1982 May; 23(3):339-47. PubMed ID: 6178853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the effect of plasminogen activator on the interaction between alpha 2-macroglobulin and plasmin.
    Toki N; Takasugi S; Sumi H; Yamura T
    Thromb Haemost; 1978 Oct; 40(2):377-86. PubMed ID: 83685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary nephrotic syndrome treated with urokinase--a report of 20 cases].
    Wang LS; Chen EH; Zhou XJ
    Zhonghua Nei Ke Za Zhi; 1989 Jun; 28(6):356-9, 382. PubMed ID: 2582915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin.
    Anonick PK; Wolf B; Gonias SL
    Thromb Res; 1990 Aug; 59(3):449-62. PubMed ID: 1700488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium.
    Beller FK; Ebert C
    Eur J Obstet Gynecol Reprod Biol; 1982 May; 13(3):177-97. PubMed ID: 6178627
    [No Abstract]   [Full Text] [Related]  

  • 17. Binding of urokinase to plasma proteinase inhibitors.
    Holmberg L; Lecander I; Astedt B
    Scand J Clin Lab Invest; 1980; 40(8):743-7. PubMed ID: 6169139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
    J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2-plasmin inhibitor complex in plasma.
    Takahashi H; Takizawa S; Hanano M; Tatewaki W; Nagasaki Y; Sasagawa Y; Shibata A
    Tohoku J Exp Med; 1987 Dec; 153(4):295-302. PubMed ID: 2964745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Abe S; Takahashi E; Handa S; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Angiology; 1994 Apr; 45(4):273-81. PubMed ID: 8161005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.